United Kingdom · Question · Written question
UIN 35581
Obesity: Drugs
Original
Introduced
4 March 2025
Last action
10 March 2025 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
10 March 2025
Summary
To ask the Secretary of State for Health and Social Care, what discussions he has had with NICE on expanding the list of weight-related comorbidities on their tirzepatide guidance to include polycystic ovarian syndrome.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
4 March 2025
Written question
To ask the Secretary of State for Health and Social Care, what discussions he has had with NICE on expanding the list of weight-related comorbidities on their tirzepatide guidance to include polycystic ovarian syndrome.
Source: Commons
10 March 2025
Answer
The National Institute for Health and Care Excellence (NICE) has published technology appraisal guidance that recommends tirzepatide to treat obesity, alongside a reduced calorie-diet and increased physical activity, in adults with a body mass index of 35...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2025-03-04/35581
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1781136
- uk · wq-1781136 · source updated 10 March 2025